| Message: | The intravenous (i.v.) self-administration has become the “gold standard” in preclinical assessment of abuse liability and is a primary method recommended by the U.S. Food and Drug Administration for use in screening novel compounds. At Creative Biolabs, we have successfully established this widely used animal model of abuse potential to provide preclinical evaluation and screening services to the clients.
To determine whether the compound will be self-administered is a key component of the preclinical abuse liability assessment. The goal of self-administration is to assess the ability of the drug to serve as a reinforcer, which determines whether drug delivery maintains behavior at a meaningfully higher rate than does in the control (usually vehicle delivery). This intravenous self-administration model is seen as valid because most drugs that are abused in humans are self-administered by laboratory animals, and most drugs that are not self-administered by laboratory animals are not abused by humans. https://www.creative-biolabs.com/drug-discovery/therapeutics/intravenous-self-administration.htm
|
my account
